Retrospective analysis confirmed monocyte to hemoglobin and neutrophil-lymphocyte ratios effectively diagnose non-small cell lung cancer, suggesting improved diagnostics with combined markers.
Objective: To evaluate the diagnostic utilities of monocyte to hemoglobin ratio (MHR) and neutrophil–lymphocyte ratio to albumin ratio (NLRAR) in the detection of non-small cell lung cancer (NSCLC). Methods: We retrospectively collected and analyzed the clinical and laboratory data, including 196 NSCLC cases and 204 controls. Results: The area under the curve (AUC) for 95% confidence interval (95% CI) of MHR and NLRAR in the diagnosis of NSCLC were found to be 0.822 (0.781–0.864) and 0.712 (0.662–0.762), respectively. The combined use of MHR, NLRAR, and carcinoma embryonic antigen (CEA) exhibited higher diagnostic sensitivity (AUC: 0.855; 95% CI: 0.818–0.892; sensitivity: 70.4%; specificity: 89.2%) than the use of individual markers or two markers combined. MHR was a potential biomarker to detect early-stage NSCLC. Conclusions: MHR and NLRAR are effective auxiliary biomarkers to predict the presence of NSCLC. When these markers are combined with CEA the diagnostic effects will further improve.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: